tirzepatide cv outcomes trial In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT Effects of Tirzepatide on the

Name: tirzepatide cv outcomes trial In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT Effects of Tirzepatide on the
Brand: italiamoderata.it
SKU: 47274397811
Price: 28.82 USD
Availability: InStock
Rating: 4.5256 (15 reviews)

SKU: 47274397811

4.5

USD28.82 USD78.82

Pay in 4 interest-free payments of $7.21 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Live Spec

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity Circulation Bridging the gap between GLP1 receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide Cardiovascular Diabetology Springer Nature Link Cardiovascular Outcomes in Adults With Type 2 Diabetes Treated With Tirzepatide: A Systematic Review and Meta Analysis of Real World Studies ScienceDirect Tirzepatide CV Outcomes: Noninferior to Dulaglutide in T2D Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS CVOT) NEJM Med Journal Club

Store: italiamoderata.it · Domain: italiamoderata.it

Description

Panellists: - William Mpute, President/ Program Coordinator, Pharmaceutical Society of Malawi/Akros, Malawi - Refiloe Mogale, Executive Director, Pharmaceutical Society of South Africa, South Africa Watch video Website Digital event video 23 October 2025, 13:00 - 14:00 CEST Awardee Talk - Exceptional Award for Education Young Career More This digital event is planned to provide a platform for the recipient of the Exceptional Award for Education - Young Career category of FIP from the Academic Pharmacy Section to provide an overview of his research and research interests to the academic and research community